Weber LUMIN Electric Grill Wins Prestigious Red Dot Award for Product Design
16.5.2024 16:00:00 CEST | Business Wire | Press Release
Weber LLC, the global leader in outdoor cooking innovation, technology, and products, announced today its LUMIN electric grill received a Red Dot Award in the Red Dot Award: Product Design 2024 competition. The Red Dot Design Award, established in 1955, is one of the world’s largest and most prestigious design competitions, receiving more than 20,000 annual submissions from approximately 60 countries worldwide.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240516349562/en/
The Weber LUMIN electric grill received a Red Dot Award in the Red Dot Award: Product Design 2024 competition. (Photo: Business Wire)
The Weber LUMIN electric grill, featuring a sleek, space-efficient, contemporary silhouette, received the Red Dot Award for its innovative and high-quality design. It is an ideal grill for outdoor cooks with limited space who desire eco-conscious fuel choices, or who live in a location where other forms of grilling are not permitted.
ABOUT THE LUMIN ELECTRIC GRILL
The LUMIN electric grill, introduced in 2023, is a highly versatile, multifunctional product. Its ultra-modern, space-efficient design makes it ideal for smaller outdoor areas such as balconies and terraces.
To create a “next-level” electric cooking experience, Weber product experts engineered this first-of-its-kind grill to:
- Reach high heat temperatures of more than 600°F/315°C so that cooks can achieve that mouthwatering, authentically grilled flavor they have come to love with Weber products; owners can reach high heat-searing temperatures within 15 minutes.
- Infuse vegetables and proteins with rich, smokey tastes through a unique smoke mode.
- Steam vegetables, braise sausages, and keep cooked food warm via different cook settings and specially designed accessories.
- Thaw frozen foods directly on the grill while it preheats to save time and simplify mealtime.
- Make clean-up easy with a front-access grease tray and dishwasher-friendly, porcelain-enamel cast iron cooking grates.
The LUMIN electric grill also features a porcelain-enamel steel lid and cookbox for superior durability and long-term corrosion resistance.
The LUMIN electric grill is available for purchase on weber.com and from retail partners across the Americas and Europe. Outdoor cooks can select from full-size or compact models and a variety of vibrant colors, including Ice Blue, Deep Ocean Blue, Golden Yellow, Seafoam Green, Crimson, and timeless Black. Available models and colors vary by geographic region.
ABOUT RED DOT DESIGN AWARDS
Every year, the renowned Red Dot Award: Product Design honors products that impress with their exceptionally high design quality. The award is based on the decision of the Red Dot jury, which consists of 39 experts from 20 countries on four continents. The experts assess the submissions based on the four basic principles of good design: the quality of function, the quality of seduction, the quality of use and the quality of responsibility.
ABOUT WEBER LLC
Weber LLC, headquartered in Palatine, Ill., is the world’s leading barbecue brand. The Company’s founder George Stephen, Sr., established the outdoor cooking category when he invented the original kettle charcoal grill more than 70 years ago. Weber offers a comprehensive, innovative product portfolio, including charcoal, gas, pellet, electric grills, smokers, griddles and accessories, designed to bring people together to create amazing memories and delicious food. Weber offers its products, services and experiences to a passionate community of millions across 78 countries.
WEBER and LUMIN are registered U.S. and EU trademarks owned by Weber-Stephen Products LLC. WEBER and LUMIN are also the subject of registrations or pending applications in other countries.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240516349562/en/
Contact information
Kristina Peterson-Lohman
media@weber.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press Release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press Release
Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press Release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press Release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press Release
Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom